丹七片治疗冠心病PPARs-PGC1α通路的分子调控机制与物质基础研究

结题报告

项目介绍

AI项目解读

基本信息

批准号：
81673712
项目类别：
面上项目
资助金额：
67.0万
负责人：
王勇
依托单位：
北京中医药大学
学科分类：
H3301.中西医结合基础理论
结题年份：
2020
批准年份：
2016
项目状态：
已结题
起止时间：
2017-01-01 至2020-12-31

项目参与者：
张小白；李鹏；王其艳；王媛媛；石天娇；卢令慧；袁少华；张倩；张怡；
关键词：
脂质代谢冠心病中药

项目摘要

Lipid metabolism disorders and chronic inflammation responses are the core of the physiological mechanism of coronary artery disease (CHD), PPARs-PGC1α pathway can regulate them simultaneously, and thus, the pathway becomes the focus of the field. Danqi pill was included in the Chinese Pharmacopoeia 2010 because of its definite efficacy on CHD, but more studies were focused on its anti-platelet effect and improvement on the heart function. In our previous study, we reported the efficacy of Danqi pills on lipid metabolism of CHD and inflammation based on the formula for the first time, but whether its pharmacological mechanism is mediated by PPARs-PCG1α pathway, the exact active components as well as the corresponding multi-targets are rarely reported. In this research, Danqi pill is used as tool drug, animal experiment is adopted to screen the potential targets or pathways comprehensively. Docking and SPACE methods et al. are employed to obtain the corresponding components reversely which based on the molecular structure. Then ADMET is used to screen the high druglikeness of the molecules containing in Chinese herbs. Drug-target regulatory networks are constructed and analyzed subsequently. After that, the relationships between drugs and targets are to be confirmed through the vitro and vivo experiments. Finally, synergistic effects and treatments of Danqi pills on CHD are clarified, which have clear components and targets. The project has important significance in proposing new treatment ideas and intervention aspects of CHD, comprehensively revealing the acting characteristics of Chinese herbs of multiple components, multiple targets, even has promising prospects on promoting the new drugs for CHD in clinical applications.

脂质代谢紊乱和慢性炎症反应是冠心病核心的病生理机制之一，PPARs-PGC1α通路因可同时调控上述机制而成为领域研究的焦点。丹七片对冠心病确有疗效被列入2010中国药典，但对其研究集中在抗血小板凝聚和改善心功能上。本课题组前期基于整方率先报道了丹七片对冠心病脂代谢和炎症的调控作用，但机制是否通过PPARs-PCG1α介导、相应的调控机制和物质基础均未见报道。本课题以丹七片为工具药，全面筛选PPARs-PCG1α通路调控脂质代谢和炎症通路效应蛋白，基于效应蛋白化学结构，采用分子docking、BATMAN等方法反向钓取起效中药成分，应用ADMET技术筛选成药性好的中药分子，构建并分析药-靶对映关系属性，结合整体/离体实验验证，最终阐明起效成分明确、作用靶标清楚的丹七片协同增效、治疗冠心病的机制。本课题对揭示丹七片药理机制与作用物质基础、中药精制与二次开发国际认可的冠心病治疗药物意义重大。

结项摘要

前期药效研究提示但其丹七片能有效改善AMI后HF大鼠左心室功能的急剧下降；同时能够减少心肌组织中的炎性细胞浸润并且显著改善心梗后心衰引起的血脂紊乱，RNA-seq结果提示丹七片是通过PPARs-RXRα通路发挥作用，提示丹七片改善AMI后HF心功能的作用机制与调控心肌能量代谢密切相关。本课题将丹七片作为工具药物，结合网络药理学和体内、体外实验验证以及SPR技术，探索其活性化合物及其靶点。本研究我们共得到9个活性化合物，并对其中的8个化合物的药靶验证得到阳性结果。在此基础上，我们发现G-Rb3不仅能通过清除自由基来保护细胞还能直接靶向RXRα靶点，激活PPARs-RXRα通路，改善AMI后HF小鼠的能量代谢紊乱。本研究从化学、分子、细胞、生物等层面研究中医药的作用机制，为中药“靶点不清，成分不明”的瓶颈问题提供了一种有前景的策略，并将为临床心衰的治疗提供替代治疗药物。